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British Columbia listing decisions for 74% of the drugs reviewed by CADTH. Ontario 
agreed with CADTH for 76% of the drugs. Positive CADTH recommendations in 
particular often translated to availability in British Columbia and Ontario. Of the 
57 drugs that received positive CADTH recommendations, 82% (47) are available in 
BC and 93% (53) are available in Ontario. Of the 36 drugs receiving negative CADTH 
recommendations, 61% (22) are unavailable in BC and 50% (18) are unavailable in 
Ontario. ConClusions: A positive CADTH recommendation is a good predictor 
of drug availability in British Columbia and Ontario. A drug that receives a nega-
tive CADTH recommendation, however, still has a significant probability of being 
listed by each province’s health care system, especially through their special access 
programs.
HC2
THe ImpaCT Of NICe’s eNd-Of-LIfe THresHOLd ON paTIeNT aCCess TO New 
CaNCer THerapIes IN eNgLaNd aNd waLes
Stewart G., Eddowes L., Hamerslag L., Kusel J.
Costello Medical Consulting Ltd., Cambridge, UK
objeCtives: In January 2009 NICE introduced supplementary advice to aid patient 
access to end-of-life treatments. The advice allowed existing cost-effectiveness 
thresholds, with an estimated upper limit of £30,000 per QALY, to be extended to 
treatments indicated for patients with a short life expectancy, provided they apply to 
small patient populations and are shown to extend life by at least 3 months. Previous 
research has determined this extended threshold to be around £50,000 per QALY. 
The aim of this study was to investigate the trends in end-of-life appraisals and 
recommendations since their introduction in 2009. Methods: NICE single tech-
nology appraisals for cancer therapeutics were reviewed from 2008 to 2013. ICERs 
were extracted from appraisals evaluated against the end-of-life criteria. Results: 
During the timeframe considered, 31 appraisals were evaluated against the end-
of-life criteria. Of the 21 appraisals considered to meet the criteria, 13 were recom-
mended for use on the NHS, with ICERs ranging from £31,800 to £51,800 per QALY. 
However, between 2009 and 2013, the average yearly ICERs for end-of-life appraisals 
increased from £41,633 to £72,667. This general increase was reflected by a subse-
quent decrease in approved treatments over time. Between 2010 and 2012, 8 end-
of-life treatments were approved; this is compared to 5 recommendations issued 
in 2009 alone. In 2013, no new end-of-life treatments were approved by NICE, with 
a lowest ICER in the submitted appraisals of £50,200 per QALY. ConClusions: The 
general trend of increasing ICERs in new end-of-life cancer appraisals has resulted 
in fewer treatments being approved by NICE in recent years. Given the limiting effect 
this could have on improving patient access, this may mean that patients need to 
rely on other funding sources, such as the Cancer Drug Fund in England, to access 
novel cancer therapeutics.
HC3
INCeNTIvIzINg vaLue IN maNaged Care drug fOrmuLarIes: desIgN, 
ImpLemeNTaTION, aNd fIrsT-Year OuTCOmes Of a vaLue-Based 
fOrmuLarY
Watkins J.1, Sullivan SD.2, Yeung K.3, Ramsey S.4, Garrison L.2, Wong E.1, Murphy C.1, 
Danielson D.1, Veenstra DL.3, Vogeler C.1, Burke W.5, McGee R.1
1Premera Blue Cross, Mountlake Terrace, WA, USA, 2School of Pharmacy, University of 
Washington, Seattle , WA, USA, 3University of Washington, Seattle, WA, USA, 4Fred Hutchinson 
Cancer Research Center and Professor, Department of Medicine, University of Washington, Seattle, 
WA, USA, 5School of Medicine, University of Washington, Seattle, WA, USA
objeCtives: Increases in drug cost sharing without regard to value may produce 
adverse financial and informational incentives which could increase health plan 
costs and worsen health outcomes in the long term. In an attempt to align utiliza-
tion with value, Premera Blue Cross, a large not-for-profit health plan in the Pacific 
Northwest, implemented a value based formulary (VBF) which utilizes cost-effec-
tiveness analysis to determine the evidence-based value of each individual drug. The 
value of each drug is used to determine the corresponding formulary tier placement 
for the drug. The objective of this study is describe the design, implementation and 
first-year outcomes of Premera’s VBF. Methods: We compared observed pharmacy 
cost per member per month (PMPM) in the year following VBF implementation to 
observed pharmacy costs twelve months prior and to an expected counterfactual 
estimate if no changes were made to the pharmacy benefits. The counterfactual 
estimate was generated using autoregressive integrated moving average applied 
to prior thirty-six months pharmacy costs. We assessed drug use and adherence 
among individuals with diabetes, hypertension, or dyslipidemia utilizing an inter-
rupted time series design with a comparison group composed of members from 
three employer groups which had the same pharmacy copay increases but did 
not implement a VBF. Results: Premera pharmacy costs decreased by 3% or 11% 
PMPM compared to the twelve months prior or counterfactual estimate respectively. 
Among individuals with diabetes, hypertension, or dyslipidemia in the VBF cohort, 
there was no significant decline in adherence or number of users of medications for 
the treatment of diabetes, hypertension, or dyslipidemia. ConClusions: Despite 
an overall higher member cost share structure and potential health plan savings, 
the VBF was potentially able to maintain medication utilization in key disease states. 
Subsequent analyses utilizing longer follow-up and greater control for confounding 
will establish more valid estimates of outcomes and costs.
HC4
THe pOTeNTIaL ImpaCT Of reCOmmeNdaTIONs made THrOugH THe 
COmmON drug revIew prOgram aT THe CaNadIaN ageNCY fOr drugs 
aNd TeCHNOLOgIes IN HeaLTH
Agarwal A.1, Coyle D.2, Lee KM.1
1Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 2University of 
Ottawa, Ottawa, ON, Canada
objeCtives: The Common Drug Review (CDR), a pan-Canadian program at the 
Canadian Agency for Drugs and Technologies in Health (CADTH), assesses the clini-
cal effectiveness, cost effectiveness and patient evidence of new drugs to provide 
dB3
a spaTIaL dIsTrIBuTION Of aduLT OBesITY prevaLeNCe IN deNver 
COuNTY, COLOradO: aN empIrICaL BaYes apprOaCH
Tabano DC.1, Barrow JC.1, Daley MF.2
1Kaiser Permanente, Denver, CO, USA, 2Kaiser Permanente Institute for Health Research, Denver, 
CO, USA
objeCtives: Measuring obesity prevalence across geographic areas must take into 
account environmental and socioeconomic factors that contribute to spatial auto-
correlation across neighboring areas. Dependency among observations across a 
geographic area violates statistical independence assumptions and bias estimates. 
Empirical Bayes estimators “smooth” variables with spatial autocorrelation, which 
limits the overall mean square-error and controls for bias estimates. Methods: 
Using a new system for BMI surveillance in Colorado, we modeled the spatial auto-
correlation of adult (≥ 18 years old) obesity (BMI ≥ 30 kg m-2) in Denver County using 
patient-level electronic health record data from Kaiser Permanente Colorado (KPCO) 
between 2009-2011. We used an Empirical Bayes tool to calculate smoothed obesity 
prevalence across census tracts. SAS 9.2 was used to clean and aggregate data. 
GeoDa was used to calculate the Moran’s I statistic to test for spatial autocorrelation 
across census tracts and smooth BMI data. KP Maps was used to map smoothed 
obesity prevalence. Results: Among patients with a valid BMI, we measure patient 
counts > = 10 across 143 census tracts in Denver County, for a total sample size of 
46,241 adults. Crude obesity prevalence for adults was 27.01% (95% CI 25.50-28.51%) 
and ranged from 10.98-45.73% across census tracts. Smoothed obesity prevalence 
was 26.93% (95% CI 25.63-28.24) and ranged from 13.19-42.03%. The Moran’s I statistic 
for crude obesity prevalence was 0.7407 (p ≤ 0.001) and the Moran’s I statistic for the 
smoothed obesity prevalence was 0.7469 (p ≤ 0.001), suggesting adult obesity preva-
lence in Denver County is distributed in a non-random pattern. ConClusions: 
Results reveal smoothed obesity prevalence for adults are non-random in Denver 
County at the census tract level. Clusters of smoothed obesity are highly significant 
(alpha= 0.05) in neighboring census tracts of high obesity prevalence. Concentrations 
of obesity are primarily in the west and northeast of the county, with less clustering 
of obesity in the central and southern parts of the county.
dB4
THe appLICaTION Of NaTuraL LaNguage prOCessINg (NLp) TeCHNOLOgY 
TO eNrICH eLeCTrONIC medICaL reCOrds (emrs) fOr OuTCOmes researCH 
IN ONCOLOgY
Hirst C.1, Hill J.2, Khosla S.1, Schweikert K.2, Senerchia C.2, Kitzmann K.2, Zhang Q.1
1AstraZeneca, Macclesfield, UK, 2Humedica, Boston, MA, USA
objeCtives: Many studies which use EMRs to evaluate oncology patients and prac-
tises have caveats around partial/missing observations within patient records. We 
describe an approach to build a potentially richer oncology dataset, supplementing 
EMR with case note observations through the use of NLP, applied specifically for 
the capture of molecular data. Methods: NLP concepts are identified and created 
based on broad topics such as medications, signs, disease and symptoms, measure-
ments and observations. The data is harvested from the notes fields within the dei-
dentified EMRs (including inpatient, clinics, pathological etc.) provided to Humedica 
from over 25 large health care systems throughout the United States. Each NLP 
concept included in the data is associated with a unique subject record and a date of 
observation; allowing longitudinal tracking of concepts such as a molecular entities. 
Data from NLP are linked to patient EMR records to allow inclusion of the additional 
variables in further analyses. The method was applied to identify molecular test-
ing data in a specific cancer type. Results: Of the 18,068 included patients with 
valid clinical notes for interrogation, patient notes for 1,027 were observed to have 
a defined observation of a molecular test specific for the target of interest; 46.3% 
(475) of which were deemed positive (i.e. indicating presence of the molecular tar-
get); 41.5% (426) negative; and 12.3% (126) with unknown status. ConClusions: 
Innovative algorithms, technical skills and clinical knowledge are required in the 
generation and analysis of oncology disease data, and NLP can allow enrichment 
with variables which are not included in EMR, allowing more detailed understand-
ing of patient cohorts. We have described an approach deemed to be successful in 
identifying cohorts of oncology patients with researchable molecular characteristics. 
Further correlating evidence and cross validation will determine the robustness and 
representativeness of the data generated with this approach.
HeaLTH Care pOLICY sTudIes
HC1
CadTH reCOmmeNdaTIONs as predICTOrs fOr drug avaILaBILITY IN 
BrITIsH COLumBIa aNd ONTarIO
Liden D., Jaksa A., Daniel K., Ho Y.
Context Matters, Inc., New York, NY, USA
objeCtives: The Canadian Agency for Drugs and Technologies in Health (CADTH) 
conducts health technology assessments and provides recommendations for 
drug listing and reimbursement. However, the health care providers of individual 
Canadian provinces are not obligated to follow CADTH recommendations. The aim 
of this analysis is to assess the value of CADTH recommendations as predictors for 
drug availability in British Columbia and Ontario. Methods: This study included 
93 CADTH recommendations for 88 drugs across 30 disease conditions. The British 
Columbia and Ontario formularies and special access programs were searched for 
these 88 drugs (some drugs were included more than once as CADTH reviewed 
them for multiple indications). Agreement was defined as any case in which drugs 
received positive CADTH recommendations and were listed by a province’s health 
care system or in which they received negative recommendations and were not 
listed. A CADTH recommendation was only considered “negative” when CADTH 
specifically recommended that a drug not be listed. Results: CADTH recom-
mendations are significantly associated with both British Columbia’s drug listings 
(p< .01) and Ontario’s drug listings (p< .01). CADTH recommendations agreed with 
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ing of perspectives and rationales for decisions. Intended to measure value in its 
broad sense, the framework supports sustained application of MCDA in health care 
decisionmaking.
HT3
IdeNTIfYINg reCeNT TreNds IN HeaLTH TeCHNOLOgY assessmeNTs fOr 
CrOHN’s dIsease
Mahendraratnam N., Inocencio TJ., Gaffney J, Agatep BC., Hughes KE.
Avalere Health LLC, Washington, DC, USA
objeCtives: To identify the types of coverage recommendations made by key 
ex-US health technology assessment (HTA) organizations for biologic treatments 
in Crohn’s disease (CD) and to understand how these organizations interpret evi-
dence to support these recommendations. Methods: Publicly available HTAs on 
CD from January 2009 to June 2013 for the following organizations were reviewed: 
CADTH (Canada), CONITEC (Brazil), HAS (France), IQWiG (Germany), NICE (UK), PBAC 
(Australia), and ISCIII (Spain). HTAs were identified using an HTA search engine 
and were supplemented with separate manual searches for CD-related reports on 
each HTA organization’s website. When additional context was needed to evaluate 
the HTA with the most recent recommendations, older HTAs were identified and 
reviewed. For each organization, the recommendation and corresponding clinical 
and economic rationales were reviewed and extracted. Results: In total, nine HTAs 
were reviewed across five organizations; no HTAs on CD from IQWiG or ISCIII were 
identified. All HTAs endorsed the use of infliximab and adalimumab for CD from a 
clinical perspective. Recommendations for subpopulations including fistulizing dis-
ease, pediatrics, and prior/concurrent corticosteroid use varied. Recommendations 
were consistent with the host country’s approved labeled indications when appro-
priate cost thresholds were met, with the exception of PBAC, where adalimumab was 
additionally deemed appropriate for fistulizing disease, and CONITEC, where certoli-
zumab was not endorsed due to safety concerns. Research gaps identified include 
the lack of head-to-head trials for adalimumab vs. infliximab and the paucity of 
long-term clinical and economic evidence. ConClusions: Infliximab and adali-
mumab generally received positive endorsements in CD, despite being frequently 
scrutinized by HTA organizations for their high costs. The expiration of patents and 
the introduction of biosimilars will likely shift how HTA entities evaluate clinical, 
economic, and humanistic evidence for biologic treatments for CD in the future.
HT4
COsT-effeCTIveNess revIews BY HTa ageNCIes: a COmparIsON Of 
faCTOrs LeadINg TO uNfavOuraBLe revIews fOr ONCOLOgY ageNTs
Smith N., Beckerman R.
CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to identify factors leading to unfa-
vourable reviews of cost-effectiveness analyses (CEAs) for oncology products by 
comparing recent summary reports from multiple HTA agencies. Methods: We 
utilised reports issued by HTA agencies of the UK (NICE), Scotland (SMC), Canada 
(pCODR), and Australia (PBAC) for this study due to their detailed and publicly avail-
able evaluations of CEA submissions. We examined the factors driving unfavourable 
appraisals by comparing recent reports of 13 selected oncology drugs launched 
between January 2012 and December 2013. The following factors were examined and 
compared as predictors for negative decisions: (1) nature of the modelled patient 
population, (2) comparator selection, (3) survival analysis approach, and (4) sensi-
tivity analyses performed. Results: Issues related to one or more of these factors 
were often cited as leading to higher and more uncertain ICER values that HTA 
bodies viewed unfavourably. The SMC and NICE frequently took issue whether the 
patient populations sourced as inputs into the CEAs were representative of the 
intended indication in each respective country. All HTA agencies took issue with 
survival analysis methods that assumed a carry-over of benefit into post-treatment 
states. Similarly, HTA bodies typically critically examined the extrapolation meth-
odology of studies with immature survival data. Although various combinations 
of these identified factors were likely to lead to negative HTA decisions, robust 
sensitivity analyses (especially regarding extrapolation methods and input sources) 
that clearly identified the factors driving ICER values were cited favourably by HTA 
agencies. ConClusions: Manufacturers must carefully select the survival analy-
sis approach that is suitable for their asset given the clinical data available, such 
that the benefit of their product is not overstated; performing robust sensitivity 
analyses to account for uncertainty may help to maximise favourable HTA appraisal 
outcomes in CEA markets.
medICaTION adHereNCe sTudIes
ma1
NON-adHereNCe Is assOCIaTed wITH pOOrer HeaLTH OuTCOmes amONg 
wOmeN CurreNTLY TreaTed fOr BreasT CaNCer wITH OraL eNdOCrINe 
THerapY
Goren A1, Geynisman DM2
1Kantar Health, New York, NY, USA, 2Fox Chase Cancer Center Temple Health, Philadelphia, PA, 
USA
objeCtives: Non-adherence rates with oral endocrine therapy (ET) in women 
with breast cancer (BC) are 25%-50% and lead to inferior survival. Understanding 
the effect of non-adherence on health outcomes is necessary to develop effec-
tive interventions. This study examined real-world non-adherence and health 
outcomes among women using ET. Methods: Female respondents from the 
2010-2012 U.S. National Health and Wellness Survey were included if reporting a 
diagnosis of BC and treatment with aromatase inhibitors (n= 261), selective estrogen 
receptor modulators (n= 113), or their combination (n= 7). The Morisky Medication 
Adherence Scale (MMAS-4 or MMAS-8, modified for use in oncology) was used to 
assess adherence, standardized using z-scores. Descriptive analyses examined 
adherence, sociodemographics, and health behaviors. Bivariate analyses com-
formulary listing recommendations to publicly funded drug plans. This study aims 
to determine the implications of implementing CDR recommendations. Methods: 
CDR reviews from December 2010 to December 2012, for which an economic evalu-
ation was submitted by the manufacturer, were assessed. A framework was devel-
oped where templates were created in Microsoft Excel for each drug submission to 
consider two scenarios: an uptake scenario (CDR recommendation implemented), 
and a counterfactual scenario (CDR recommendation not implemented). Drug costs 
and quality adjusted life years (if applicable) for both scenarios were determined at 
the population level using patient numbers reported in the manufacturer’s budget 
impact analyses. The incremental net benefit was calculated, based on a willing-
ness-to-pay of $50,000. In addition, sensitivity analyses were conducted to consider 
variation around the counterfactual scenario. Results: Based on the results for the 
55 drugs for which cost-utility or a cost-minimization analysis was submitted, the 
total incremental net benefit of implementing a CDR recommendation was calcu-
lated to be over 1 billion dollars over a 1-year time frame for participating provincial 
drug plans. Detailed sensitivity analysis explored the uncertainty around these 
estimates. ConClusions: Overall, the 10 drug plans included for this analysis 
would realize significant benefit by implementing CDR recommendations. Based 
on this research, a framework to assess the impact of CDR recommendations is 
being developed. Next steps include, consideration of disease specific estimates 
of net benefit and the inclusion of all participating drug plans to provide broader 
implications of overall CDR impact in Canada.
HeaLTH TeCHNOLOgY assessmeNT sTudIes
HT1
reCeNT HeaLTH TeCHNOLOgY assessmeNT deCIsIONs aCrOss THe gLOBe: 
a fOCus ON ONCOLOgY
Clark RS., Zagadailov E., Bramley T.
Xcenda, Palm Harbor, FL, USA
objeCtives: Due to a substantial oncology burden across the globe, there is an 
increasing need for innovative, more effective oncology treatments. Although the 
decision-making process differs among nations, health technology assessments 
(HTAs) aim to produce policies that achieve optimal value while improving patient 
care and health outcomes. The objective of this analysis was to evaluate recent 
patterns in oncology-based HTA decisions in selected countries. Methods: HTA 
surveillance was conducted for Australia, Canada, France, Germany, and the United 
Kingdom (UK) from January 1, 2012 to August 31, 2013 (19 months). Oncology-based 
HTAs were evaluated by therapeutic area, decision, and rationale for the decision. 
Decisions were categorized as favorable, unfavorable, mixed (ie, both favorable 
and unfavorable), and neutral (ie, deferral). Results: 67 oncology-related HTAs 
were published in the study timeframe. Across studied nations, 38 (57%) decisions 
were favorable, 25 (37%) unfavorable, 1 (1%) mixed, and 3 (4%) neutral. Of those 
unfavorable decisions, 13 were rejected for insufficient benefit to justify the high 
cost (ie, improperly high incremental cost-effectiveness ratio [ICER]), 9 for insuf-
ficient or unproven clinical benefit vs the most appropriate comparator, and 3 for 
incomplete or improper submission. Excluding mixed and neutral decisions, France 
was associated with the highest percentage of favorable decisions (14 of 15; 93%), 
followed by Germany (9 of 14; 64%), Australia (11 of 20; 55%), and the UK (4 of 14; 
29%). ConClusions: Based on the last 19 months of oncology-based HTAs, over 
50% of decisions were favorable. The most significant factor leading to rejection for 
oncology products is the inability to prove cost-effectiveness vs the most appropri-
ate comparator, followed by unproven clinical benefit. This analysis suggests that 
manufacturers would have more success with HTA decisions, particularly in the UK, 
if more robust health economic and clinical data are generated.
HT2
assessINg THe vaLue Of TreaTmeNTs fOr rare dIseases usINg aN 
mCda-Based apprOaCH: meTHOdOLOgICaL aNd eTHICaL fOuNdaTIONs Of 
CrITerIa seLeCTION aNd framewOrk deveLOpmeNT
Wagner M1, Khoury H1, Willet J2, Rindress D1, Goetghebeur M1
1LASER Analytica, Montreal, QC, Canada, 2LASER Analytica, New York, NY, USA
bACkgRound: Appraising rare disease treatments involves multiple issues and 
represents a significant challenge for HTA agencies. Multicriteria-approaches are 
uniquely suited to assess their real life value. objeCtives: were to develop a frame-
work adapted to rare diseases while remaining compatible with other therapeutic 
areas for broad application. Methods: Adaptation of the framework to rare dis-
eases was based on methodological and ethical principles underlying the EVIDEM 
framework, informed by issues and policies specific to rare diseases, which were 
identified through literature review and survey, and guided by pragmatic considera-
tions of real life application in participatory processesCriteria selection followed 
MCDA principles: completeness; non-redundancy; operationalizability; and inde-
pendence. MCDA model mechanics and sensitivity analyses were designed based 
on a review of MCDA modeling. Results: Quantitative criteria of the framework are 
organized into a hierarchical MCDA model consisting of six domains of value (top-
level criteria): Need, Type of benefit, Outcomes, Economic consequences, Knowledge, and 
Established priorities. Each domain includes criteria and subcriteria, each contributing 
to the final output of the model, i.e., the Value Estimate. The model explicitly takes 
into account aspects of rare diseases, including: disease complexity; treatment 
outcomes complexity; multiple economic and social consequences; data limita-
tions and innovative approaches to tackle these; and health care system priorities. 
Weighting and scoring methodologies capture individual perspectives and judg-
ments on the meaning of data while allowing for full exploration of uncertainty 
through six types of sensitivity analyses. Qualitative criteria support consideration 
of the impact of contextual issues. ConClusions: This framework promotes a 
comprehensive, transparent and systematic appraisal of rare disease treatments 
while remaining applicable to any therapy. Although numerical outputs are pro-
duced, the framework is intended to support deliberative processes that allow shar-
